Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 3.0 | 4.0 |
Min SIP Amount | ₹99 | ₹500 |
Expense Ratio | 1.93 | 1.95 |
NAV | ₹36.85 | ₹412.09 |
Fund Started | 11 Jun 2018 | 04 Jun 1999 |
Fund Size | ₹2770.21 Cr | ₹3416.13 Cr |
Exit Load | Exit load of 1% if redeemed within 1 year. | Exit load of 0.50% if redeemed within 15 days |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 37.12% | 43.19% |
3 Year | 16.84% | 22.90% |
5 Year | 28.20% | 28.60% |
1 Year
3 Year
5 Year
Equity | 99.08% | 96.73% |
Cash | 0.92% | 3.27% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.00% |
Aurobindo Pharma Ltd. | 8.05% |
Cipla Ltd. | 6.80% |
Glenmark Pharmaceuticals Ltd. | 6.20% |
Dr. Reddy's Laboratories Ltd. | 6.05% |
Apollo Hospitals Enterprise Ltd. | 5.51% |
Lupin Ltd. | 5.30% |
Divi's Laboratories Ltd. | 4.96% |
Suven Pharmaceuticals Ltd. | 4.22% |
Krishna Institute of Medical Sciences Ltd | 3.95% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.99% |
Max Healthcare Institute Ltd. | 6.26% |
Divi's Laboratories Ltd. | 6.21% |
Poly Medicure Ltd. | 5.38% |
Lupin Ltd. | 5.12% |
Lonza Group Ag | 4.55% |
Cipla Ltd. | 4.54% |
Krishna Institute of Medical Sciences Ltd | 3.99% |
Jupiter Life Line Hospitals Ltd. | 3.54% |
Mankind Pharma Ltd. | 3.51% |
Name | Vrijesh Kasera | Tanmaya Desai |
Start Date | 03 Feb 2023 | 27 Jun 2011 |
Name
Start Date
Description | The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sectors in India. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 11 Jun 2018 | 04 Jun 1999 |
Description
Launch Date